{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:47:29Z","timestamp":1792144049626,"version":"4.4.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"DOI":"10.1007\/s11427-026-3557-6","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:52:44Z","timestamp":1792133564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["pH-responsive biomimetic liposomes enhance targeted immunotherapy of bladder cancer"],"prefix":"10.1007","author":[{"given":"Haojie","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanbao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke\u2019nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaowei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghao","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuepei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"3557_CR1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M., Roberts, E.W., Kersten, K., Chan, V., Fearon, D.F., Merad, M., Coussens, L.M., Gabrilovich, D.I., Ostrand-Rosenberg, S., Hedrick, C.C., et al. (2018). Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24, 541\u2013550.","journal-title":"Nat Med"},{"key":"3557_CR2","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s12951-025-03609-2","volume":"23","author":"H Cai","year":"2025","unstructured":"Cai, H., Xue, P., Liu, S., Ma, Y., Zeng, X., Yan, S., and Xu, N. (2025). CuOTeDsP nanotherapeutics enhance cuproptosis-mediated immunotherapy by modulating cholesterol metabolism in bladder cancer. J Nanobiotechnol 23, 534.","journal-title":"J Nanobiotechnol"},{"key":"3557_CR3","doi-asserted-by":"publisher","first-page":"8215","DOI":"10.1038\/s41467-025-62710-0","volume":"16","author":"K Chang","year":"2025","unstructured":"Chang, K., Delavan, H.M., Yip, E., Kasap, C., Zhu, J., Lodha, R., Liao, S.Y., Berman, S. C., Carretero-Gonzalez, A., Basar, M., et al. (2025). Modulating the PPAR\u03b3 pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. Nat Commun 16, 8215.","journal-title":"Nat Commun"},{"key":"3557_CR4","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1186\/s12951-025-03730-2","volume":"23","author":"D Chen","year":"2025","unstructured":"Chen, D., Jiang, H., Sun, L., Nurzat, Y., Qin, H., Zhao, Z., Liu, D., Zheng, S., Wang, L., Fu, Y., et al. (2025a). Neuron-targeted ROS-responsive liposomes for puerarin delivery remodel ischemic microenvironment via microglial modulation and neurovascular regeneration. J Nanobiotechnol 23, 677.","journal-title":"J Nanobiotechnol"},{"key":"3557_CR5","doi-asserted-by":"crossref","first-page":"eadr5635","DOI":"10.1126\/sciadv.adr5635","volume":"11","author":"F Chen","year":"2025","unstructured":"Chen, F., He, Z., Guo, R., Li, M., Li, J., Wang, Y., He, X., Tian, Z., Ling, X., Xiong, L., et al. (2025b). Extracellular vesicle-hitchhiking nanoliposomes for cancer-associated fibroblast phenotype modulation impede metastasis progression. Sci Adv 11, eadr5635.","journal-title":"Sci Adv"},{"key":"3557_CR6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41585-025-01092-w","volume":"23","author":"F Child","year":"2026","unstructured":"Child, F., Lunj, S., Gough, J., Humphries, M.J., Biolatti, L.V., Hoskin, P.J., Choudhury, A., and Quiles, C.G. (2026). The hypoxic ECM and neutrophils in MIBC immunotherapy resistance. Nat Rev Urol 23, 236\u2013255.","journal-title":"Nat Rev Urol"},{"key":"3557_CR7","doi-asserted-by":"crossref","first-page":"2538687","DOI":"10.1080\/2162402X.2025.2538687","volume":"14","author":"CE de Andrea","year":"2025","unstructured":"de Andrea, C.E., Abengozar-Muela, M., Arranz, J.\u00c1., Climent, M.A., Puente, J., Vizcay, \u00c1., Montero de la Fuente, L., Jurado, J.M., Bonfill, T., Santander, C., et al. (2025). Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients. Oncoimmunology 14, 2538687.","journal-title":"Oncoimmunology"},{"key":"3557_CR8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K.E., and Joyce, J.A. (2023). The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374\u2013403.","journal-title":"Cancer Cell"},{"key":"3557_CR9","doi-asserted-by":"crossref","first-page":"25628","DOI":"10.1021\/acsnano.5c00216","volume":"19","author":"X Dong","year":"2025","unstructured":"Dong, X., Suo, Y., Yu, J., Yu, F., Li, F., Zheng, J., Li, G., Ma, S., Hao, Y., Zhang, H., et al. (2025). Biomimetic nanoparticles simultaneously targeting modulation of lipid metabolism and phenotype of macrophages for programmed atherosclerosis management. ACS Nano 19, 25628\u201325644.","journal-title":"ACS Nano"},{"key":"3557_CR10","doi-asserted-by":"crossref","first-page":"e12230","DOI":"10.1002\/adma.202512230","volume":"38","author":"C Fang","year":"2026","unstructured":"Fang, C., Peng, Q., Li, X., Qu, X., Qiao, Z., Yin, B., Xiao, L., Chen, Y., Dong, X., Cai, L., et al. (2026). Multichannel immune nanoregulators suppress lactic acid metabolism and lactic acid-shaped acidic microenvironment to uproot anti-tumor immunosuppression. Adv Mater 38, e12230.","journal-title":"Adv Mater"},{"key":"3557_CR11","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s11427-025-3238-1","volume":"69","author":"GS Feng","year":"2026","unstructured":"Feng, G.S. (2026). Advancing liver cancer immunotherapy beyond checkpoint blockade. Sci China Life Sci 69, 2107\u20132109.","journal-title":"Sci China Life Sci"},{"key":"3557_CR12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","volume":"22","author":"TW Flaig","year":"2024","unstructured":"Flaig, T.W., Spiess, P.E., Abern, M., Agarwal, N., Bangs, R., Buyyounouski, M.K., Chan, K., Chang, S.S., Chang, P., Friedlander, T., et al. (2024). Bladder cancer, version 3.2024. J Natl Compr Cancer Netw 22, 216\u2013225.","journal-title":"J Natl Compr Cancer Netw"},{"key":"3557_CR13","doi-asserted-by":"crossref","first-page":"123677","DOI":"10.1016\/j.biomaterials.2025.123677","volume":"326","author":"R Geng","year":"2026","unstructured":"Geng, R., Shang, H., Chen, Z., Tang, K., Liu, Y., and Zhu, J. (2026). ROS-responsive resiquimod prodrug nanoparticles for macrophage reprogramming and enhanced immune checkpoint inhibitor therapy in bladder cancer. Biomaterials 326, 123677.","journal-title":"Biomaterials"},{"key":"3557_CR14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","volume":"86","author":"P Gontero","year":"2024","unstructured":"Gontero, P., Birtle, A., Capoun, O., Comp\u00e9rat, E., Dominguez-Escrig, J.L., Liedberg, F., Mariappan, P., Masson-Lecomte, A., Mostafid, H.A., Pradere, B., et al. (2024). European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update. Eur Urol 86, 531\u2013549.","journal-title":"Eur Urol"},{"key":"3557_CR15","doi-asserted-by":"crossref","first-page":"e2500257","DOI":"10.1200\/PO-25-00257","volume":"9","author":"S Gupta","year":"2025","unstructured":"Gupta, S., Lee, J.K., Mitchell, J., and Huang, R.S.P. (2025). Fibroblast growth factor receptor 3 alteration status and outcomes on immune checkpoint inhibitors in patients with metastatic urothelial carcinoma. JCO Precis Oncol 9, e2500257.","journal-title":"JCO Precis Oncol"},{"key":"3557_CR16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jconrel.2023.03.038","volume":"357","author":"SJ Hao","year":"2023","unstructured":"Hao, S.J., Zhu, Y.X., and Wu, F.G. (2023). Membrane fusion-mediated delivery of small-molecule HER2 tyrosine kinase inhibitor for effective tumor chemosensitization. J Control Release 357, 222\u2013234.","journal-title":"J Control Release"},{"key":"3557_CR17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","volume":"22","author":"T Helsten","year":"2016","unstructured":"Helsten, T., Elkin, S., Arthur, E., Tomson, B.N., Carter, J., and Kurzrock, R. (2016). The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res 22, 259\u2013267.","journal-title":"Clin Cancer Res"},{"key":"3557_CR18","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.7150\/ijbs.103274","volume":"21","author":"CY Ho","year":"2025","unstructured":"Ho, C.Y., Hwang, T.I.S., Peng, P.W., Tsai, T.F., Chou, K.Y., Chen, H.E., Chang, P.H., Huang, W.C., Hsu, C.H., Chien, T.J., et al. (2025). Antitumor effects of sesamin via the LincRNA-p21\/STAT3 axis in human bladder cancer: inhibition of metastatic progression and enhanced chemosensitivity. Int J Biol Sci 21, 2692\u20132706.","journal-title":"Int J Biol Sci"},{"key":"3557_CR19","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acsnano.0c09681","volume":"15","author":"M Hu","year":"2021","unstructured":"Hu, M., Zhang, J., Kong, L., Yu, Y., Hu, Q., Yang, T., Wang, Y., Tu, K., Qiao, Q., Qin, X., et al. (2021). Immunogenic hybrid nanovesicles of liposomes and tumor-derived nanovesicles for cancer immunochemotherapy. ACS Nano 15, 3123\u20133138.","journal-title":"ACS Nano"},{"key":"3557_CR20","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.1038\/s41467-024-50568-7","volume":"15","author":"K Jiang","year":"2024","unstructured":"Jiang, K., Tian, K., Yu, Y., Wu, E., Yang, M., Pan, F., Qian, J., and Zhan, C. (2024). Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin. Nat Commun 15, 6136.","journal-title":"Nat Commun"},{"key":"3557_CR21","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1016\/j.cell.2025.02.014","volume":"188","author":"Y Jiang","year":"2025","unstructured":"Jiang, Y., Dai, A., Huang, Y., Li, H., Cui, J., Yang, H., Si, L., Jiao, T., Ren, Z., Zhang, Z., et al. (2025). Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs. Cell 188, 2354\u20132371.e18.","journal-title":"Cell"},{"key":"3557_CR22","doi-asserted-by":"publisher","first-page":"7995","DOI":"10.1038\/s41467-025-63309-1","volume":"16","author":"T Kamatani","year":"2025","unstructured":"Kamatani, T., Umeda, K., Iwasawa, T., Miya, F., Matsumoto, K., Mikami, S., Hara, K., Shimoda, M., Suzuki, Y., Nishino, J., et al. (2025). Clonal diversity shapes the tumour microenvironment leading to distinct immunotherapy responses in metastatic urothelial carcinoma. Nat Commun 16, 7995.","journal-title":"Nat Commun"},{"key":"3557_CR23","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s11427-025-3098-4","volume":"69","author":"F Kuang","year":"2026","unstructured":"Kuang, F., Hu, Z., Huangfu, L., Yan, G., Dhiman, S., Chen, W., and Li, Z. (2026). ETV5 upregulates PD-L1 transcription to inhibit cytotoxic CD8+ T cell proliferation in colorectal cancer. Sci China Life Sci 69, 1411\u20131413.","journal-title":"Sci China Life Sci"},{"key":"3557_CR24","doi-asserted-by":"crossref","first-page":"166665","DOI":"10.1016\/j.bbadis.2023.166665","volume":"1869","author":"Y Li","year":"2023","unstructured":"Li, Y., Shi, Y., Zhang, X., Li, P., Ma, L., Hu, P., Xu, L., Dai, Y., Xia, S., and Qiu, H. (2023). FGFR2 upregulates PAI-1 via JAK2\/STAT3 signaling to induce M2 polarization of macrophages in colorectal cancer. Biochim Biophys Acta Mol Basis Dis 1869, 166665.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"3557_CR25","doi-asserted-by":"crossref","first-page":"27957","DOI":"10.1021\/acsnano.5c10591","volume":"19","author":"Y Li","year":"2025","unstructured":"Li, Y., Jia, W., Zhu, M., Hu, X., Ya, Z., Liu, Y., Zong, Y., Guo, S., and Wan, M. (2025). Focused acoustic vortex-activated dual-stimuli nanoplatform synergizes with checkpoint blockade to enhance macrophage phagocytosis and antitumor immunity. ACS Nano 19, 27957\u201327976.","journal-title":"ACS Nano"},{"key":"3557_CR26","doi-asserted-by":"crossref","first-page":"rbae135","DOI":"10.1093\/rb\/rbae135","volume":"12","author":"C Liu","year":"2025","unstructured":"Liu, C., Gao, J., Cheng, Y., Zhang, S., and Fu, C. (2025a). Homologous-adhering\/targeting cell membrane- and cell-mediated delivery systems: a cancer-catch-cancer strategy in cancer therapy. Regen Biomater 12, rbae135.","journal-title":"Regen Biomater"},{"key":"3557_CR27","doi-asserted-by":"crossref","first-page":"38594","DOI":"10.1021\/acsnano.5c13110","volume":"19","author":"Y Liu","year":"2025","unstructured":"Liu, Y., Wang, X., Xu, H., Wu, H., Ju, Y., Cui, L., Zhao, Y., Chen, Y., Cui, M., and Yang, F. (2025b). Ultrasound-visualized cuproptosis in glioblastoma via endogenous copper sequestration and nitric oxide-gas controlled release using a programmable nanoliposomal platform. ACS Nano 19, 38594\u201338613.","journal-title":"ACS Nano"},{"key":"3557_CR28","doi-asserted-by":"crossref","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran, A., Cookson, M.S., Guercio, B.J., and Cheng, L. (2024). Advances in diagnosis and treatment of bladder cancer. BMJ 384, e076743.","journal-title":"BMJ"},{"key":"3557_CR29","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot, Y., Matsubara, N., Park, S.H., Huddart, R.A., Burgess, E.F., Houede, N., Banek, S., Guadalupi, V., Ku, J.H., Valderrama, B.P., et al. (2023). Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med 389, 1961\u20131971.","journal-title":"N Engl J Med"},{"key":"3557_CR30","doi-asserted-by":"crossref","first-page":"e02289","DOI":"10.1002\/advs.202502289","volume":"12","author":"C Ma","year":"2025","unstructured":"Ma, C., Gao, L., Song, K., Gu, B., Wang, B., Yu, Y., Wang, X., Li, X., Hu, J., Pu, W., et al. (2025). Targeted dual-responsive liposomes co-deliver Jolkinolide B and Ce6 to synergistically enhance the photodynamic\/immunotherapy efficacy in gastric cancer through the PANoptosis pathway. Adv Sci 12, e02289.","journal-title":"Adv Sci"},{"key":"3557_CR31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12951-023-01993-1","volume":"21","author":"R Mo","year":"2023","unstructured":"Mo, R., Dawulieti, J., Chi, N., Wu, Z., Yun, Z., Du, J., Li, X., Liu, J., Xie, X., Xiao, K., et al. (2023). Self-polymerized platinum (II)-polydopamine nanomedicines for photochemotherapy of bladder cancer favoring antitumor immune responses. J Nanobiotechnol 21, 235.","journal-title":"J Nanobiotechnol"},{"key":"3557_CR32","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1158\/0008-5472.CAN-23-1065","volume":"83","author":"Y Ouyang","year":"2023","unstructured":"Ouyang, Y., Ou, Z., Zhong, W., Yang, J., Fu, S., Ouyang, N., Chen, J., Xu, L., Wu, D., Qian, J., et al. (2023). FGFR3 alterations in bladder cancer stimulate serine synthesis to induce immune-inert macrophages that suppress T-cell recruitment and activation. Cancer Res 83, 4030\u20134046.","journal-title":"Cancer Res"},{"key":"3557_CR33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1186\/s12951-025-03638-x","volume":"23","author":"W Pan","year":"2025","unstructured":"Pan, W., Li, C., Zhou, X., Liu, W., Liu, J., Lin, Q., Huang, J., Hao, Z., Jiang, Y., and Lin, J. (2025). Dectin-1-targeted pH-responsive liposomal nanoplatform delivering Plantage Asiatica L. acidic polysaccharide for immunomodulation and immunosuppressive breast cancer microenvironment reprogramming. J Nanobiotechnol 23, 597.","journal-title":"J Nanobiotechnol"},{"key":"3557_CR34","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles, T., Valderrama, B.P., Gupta, S., Bedke, J., Kikuchi, E., Hoffman-Censits, J., Iyer, G., Vulsteke, C., Park, S.H., Shin, S.J., et al. (2024). Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390, 875\u2013888.","journal-title":"N Engl J Med"},{"key":"3557_CR35","doi-asserted-by":"crossref","first-page":"122183","DOI":"10.1016\/j.biomaterials.2023.122183","volume":"300","author":"H Shao","year":"2023","unstructured":"Shao, H., Zhou, J., Lin, X., Zhou, Y., Xue, Y., Hong, W., Lin, X., Jia, X., and Fan, Y. (2023). Bio-inspired peptide-conjugated liposomes for enhanced planktonic bacteria killing and biofilm eradication. Biomaterials 300, 122183.","journal-title":"Biomaterials"},{"key":"3557_CR36","doi-asserted-by":"crossref","first-page":"785091","DOI":"10.3389\/fimmu.2021.785091","volume":"12","author":"AP Shi","year":"2021","unstructured":"Shi, A.P., Tang, X.Y., Xiong, Y.L., Zheng, K.F., Liu, Y.J., Shi, X.G., Lv, Y., Jiang, T., Ma, N., and Zhao, J.B. (2021). Immune checkpoint LAG3 and its ligand FGL1 in cancer. Front Immunol 12, 785091.","journal-title":"Front Immunol"},{"key":"3557_CR37","doi-asserted-by":"crossref","first-page":"31656","DOI":"10.1021\/acsnano.5c09493","volume":"19","author":"L Shu","year":"2025","unstructured":"Shu, L., Luo, P., Ren, C., Lai, Z., Zhang, X., Wu, C., Pan, X., and Huang, Z. (2025). Inhalable fibroin hybrid liposomes for the targeted treatment of lung adenocarcinoma via autophagy-enhanced ferroptosis. ACS Nano 19, 31656\u201331676.","journal-title":"ACS Nano"},{"key":"3557_CR38","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R.L., Kratzer, T.B., Giaquinto, A.N., Sung, H., and Jemal, A. (2025). Cancer statistics, 2025. CA Cancer J Clin 75, 10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"3557_CR39","doi-asserted-by":"crossref","first-page":"107968","DOI":"10.1016\/j.phrs.2025.107968","volume":"221","author":"Y Song","year":"2025","unstructured":"Song, Y., Jiang, S., Peng, Y., Du, Y., Qin, C., and Xu, T. (2025). FGFR3 alteration sites and response rate to FGFR inhibitors in urothelial carcinoma. Pharmacol Res 221, 107968.","journal-title":"Pharmacol Res"},{"key":"3557_CR40","doi-asserted-by":"crossref","first-page":"e06841","DOI":"10.1002\/advs.202506841","volume":"12","author":"M Tan","year":"2025","unstructured":"Tan, M., Shi, C., Chi, G., Su, X., Liu, F., Zhu, L., Cheng, G., Chen, X., Yu, M., Chen, Y., et al. (2025). PD-L1-targeting biomimetic photoresponsive thermosensitive liposomes for triple-negative breast cancer. Adv Sci 12, e06841.","journal-title":"Adv Sci"},{"key":"3557_CR41","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","volume":"6","author":"T Tang","year":"2021","unstructured":"Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., and Liang, T. (2021). Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Sig Transduct Target Ther 6, 72.","journal-title":"Sig Transduct Target Ther"},{"key":"3557_CR42","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.eururo.2020.07.018","volume":"78","author":"MY Teo","year":"2020","unstructured":"Teo, M.Y., Mota, J.M., Whiting, K.A., Li, H.A., Funt, S.A., Lee, C.H., Solit, D.B., Al-Ahmadie, H., Milowsky, M.I., Balar, A.V., et al. (2020). Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma. Eur Urol 78, 907\u2013915.","journal-title":"Eur Urol"},{"key":"3557_CR43","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"AG van der Heijden","year":"2025","unstructured":"van der Heijden, A.G., Bruins, H.M., Carrion, A., Cathomas, R., Comp\u00e9rat, E., Dimitropoulos, K., Efstathiou, J.A., Fietkau, R., Kailavasan, M., Lorch, A., et al. (2025). European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines. Eur Urol 87, 582\u2013600.","journal-title":"Eur Urol"},{"key":"3557_CR44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","volume":"20","author":"LMC van Hoogstraten","year":"2023","unstructured":"van Hoogstraten, L.M.C., Vrieling, A., van der Heijden, A.G., Kogevinas, M., Richters, A., and Kiemeney, L.A. (2023). Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat Rev Clin Oncol 20, 287\u2013304.","journal-title":"Nat Rev Clin Oncol"},{"key":"3557_CR45","doi-asserted-by":"crossref","first-page":"e10197","DOI":"10.1002\/advs.202510197","volume":"12","author":"D Wang","year":"2025","unstructured":"Wang, D., Liu, Y., Chen, Y., Dai, C., Hu, W., Han, J., Li, Z., Yin, F., Zhang, Y., and Shi, C. (2025). EGFR targeted liposomal PROTAC assisted with epigenetic regulation as an efficient strategy for osimertinib-resistant lung cancer therapy. Adv Sci 12, e10197.","journal-title":"Adv Sci"},{"key":"3557_CR46","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jconrel.2024.02.029","volume":"368","author":"H Wang","year":"2024","unstructured":"Wang, H., Wu, X., Sun, Y., Liu, A., He, Y., Xu, Z., Lu, Y., and Zhan, C. (2024a). A natural IgM hitchhiking strategy for delivery of cancer nanovaccines to splenic marginal zone B cells. J Control Release 368, 208\u2013218.","journal-title":"J Control Release"},{"key":"3557_CR47","doi-asserted-by":"crossref","first-page":"122477","DOI":"10.1016\/j.biomaterials.2024.122477","volume":"306","author":"Z Wang","year":"2024","unstructured":"Wang, Z., Li, W., Jiang, Y., Tran, T.B., Chung, J., Kim, M., Scott, A.J., and Lu, J. (2024b). Camptothesome-based combination nanotherapeutic regimen for improved colorectal cancer immunochemotherapy. Biomaterials 306, 122477.","journal-title":"Biomaterials"},{"key":"3557_CR48","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s11427-023-2474-4","volume":"67","author":"Q Wei","year":"2024","unstructured":"Wei, Q., Xue, C., Li, M., Wei, J., Zheng, L., Chen, S., Duan, Y., Deng, H., Tang, F., Xiong, W., et al. (2024). Ferroptosis: a critical mechanism of N6-methyladenosine modification involved in carcinogenesis and tumor progression. Sci China Life Sci 67, 1119\u20131132.","journal-title":"Sci China Life Sci"},{"key":"3557_CR49","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s11427-025-3059-3","volume":"69","author":"G Wu","year":"2026","unstructured":"Wu, G., Li, H., Liang, Y., Li, S., Li, X., and Saw, P.E. (2026). Liposomes in tumor treatment: a double-edged sword. Sci China Life Sci 69, 1921\u20131928.","journal-title":"Sci China Life Sci"},{"key":"3557_CR50","doi-asserted-by":"crossref","first-page":"e11181","DOI":"10.1002\/adma.202511181","volume":"37","author":"Y Wu","year":"2025","unstructured":"Wu, Y., Zhang, Y., Han, J., Jiang, Y., Chen, M., Gu, X., Jiang, W., Fan, K., and Liu, B. (2025). Nanozyme-based biomimetic intelligent immune organelles for the treatment of bladder-metastasized tumors. Adv Mater 37, e11181.","journal-title":"Adv Mater"},{"key":"3557_CR51","doi-asserted-by":"crossref","first-page":"e2500021","DOI":"10.1002\/advs.202500021","volume":"12","author":"Y Xu","year":"2025","unstructured":"Xu, Y., Wang, B., Huang, Y., Liao, J.P., Wu, C., Zhou, C., Kang, Z., Jiang, S., Wu, B.C., Zhang, D., et al. (2025). Targeting antigen-presenting cells to enhance the tumor-spleen immunity cycle through liposome-neoantigen vaccine. Adv Sci 12, e2500021.","journal-title":"Adv Sci"},{"key":"3557_CR52","doi-asserted-by":"crossref","first-page":"123289","DOI":"10.1016\/j.biomaterials.2025.123289","volume":"321","author":"L Yang","year":"2025","unstructured":"Yang, L., Wang, P., Zhang, Y., Zhou, J., Bi, X., Qian, Z., Hou, S., Li, L., and Fan, Y. (2025). Hybrid cell membrane coating orchestrates foreign-body reactions, anti-adhesion, and pro-regeneration in abdominal wall reconstruction. Biomaterials 321, 123289.","journal-title":"Biomaterials"},{"key":"3557_CR53","doi-asserted-by":"crossref","first-page":"e2205449","DOI":"10.1002\/advs.202205449","volume":"10","author":"X Yang","year":"2023","unstructured":"Yang, X., Bian, J., Wang, Z., He, M., Yang, Y., Li, Q., Luo, X., Zhou, Z., Li, J., Ju, S., et al. (2023). A bio-liposome activating natural killer cell by illuminating tumor homogenization antigen properties. Adv Sci 10, e2205449.","journal-title":"Adv Sci"},{"key":"3557_CR54","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/s41467-025-56768-z","volume":"16","author":"Y Yuan","year":"2025","unstructured":"Yuan, Y., Lin, Q., Feng, H.Y., Zhang, Y., Lai, X., Zhu, M.H., Wang, J., Shi, J., Huang, Y., Zhang, L., et al. (2025). A multistage drug delivery approach for colorectal primary tumors and lymph node metastases. Nat Commun 16, 1439.","journal-title":"Nat Commun"},{"key":"3557_CR55","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1186\/s12951-025-03756-6","volume":"23","author":"CG Zhang","year":"2025","unstructured":"Zhang, C.G., Yeh, C.Y., Hsu, S.Y., Prakash, M., Abarientos, A.B., Chiang-Hsieh, H.M., Lin, Y.Y., Ortiz, C.L.D., Yang, L.W., Liang, P.H., et al. (2025a). Dendritic cell-targeted liposomes for cancer immunotherapy via inhibition of aryl hydrocarbon receptor. J Nanobiotechnol 23, 683.","journal-title":"J Nanobiotechnol"},{"key":"3557_CR56","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2011.05.013","volume":"414","author":"H Zhang","year":"2011","unstructured":"Zhang, H., Wang, Z., Gong, W., Li, Z., Mei, X., and Lv, W. (2011). Development and characteristics of temperature-sensitive liposomes for vinorelbine bitartrate. Int J Pharm 414, 56\u201362.","journal-title":"Int J Pharm"},{"key":"3557_CR57","doi-asserted-by":"crossref","first-page":"122801","DOI":"10.1016\/j.biomaterials.2024.122801","volume":"313","author":"L Zhang","year":"2025","unstructured":"Zhang, L., Shi, J., Zhu, M.H., Huang, Y., Lu, Q., Sun, P., Chen, H.Z., Lai, X., and Fang, C. (2025b). Liposomes-enabled cancer chemoimmunotherapy. Biomaterials 313, 122801.","journal-title":"Biomaterials"},{"key":"3557_CR58","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1038\/s41401-020-00574-4","volume":"42","author":"WT Zhang","year":"2021","unstructured":"Zhang, W.T., Liu, T.T., Wu, M., Chen, X.C., Han, L., Shi, Z.Z., Li, Y.Y., Li, X.Y., Xu, H. X., Gong, L.K., et al. (2021). Development of a nanobody-based immunoassay for the sensitive detection of fibrinogen-like protein 1. Acta Pharmacol Sin 42, 1921\u20131929.","journal-title":"Acta Pharmacol Sin"},{"key":"3557_CR59","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/s41596-022-00713-7","volume":"17","author":"X Zhao","year":"2022","unstructured":"Zhao, X., Zhao, R., and Nie, G. (2022). Nanocarriers based on bacterial membrane materials for cancer vaccine delivery. Nat Protoc 17, 2240\u20132274.","journal-title":"Nat Protoc"},{"key":"3557_CR60","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jconrel.2024.01.049","volume":"367","author":"XY Zhu","year":"2024","unstructured":"Zhu, X.Y., Wang, T.Y., Jia, H.R., Wu, S.Y., Gao, C.Z., Li, Y.H., Zhang, X., Shan, B.H., and Wu, F.G. (2024). A ferroptosis-reinforced nanocatalyst enhances chemodynamic therapy through dual H2O2 production and oxidative stress amplification. J Control Release 367, 892\u2013904.","journal-title":"J Control Release"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-026-3557-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-026-3557-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-026-3557-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:13:57Z","timestamp":1792142037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-026-3557-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":60,"alternative-id":["3557"],"URL":"https:\/\/doi.org\/10.1007\/s11427-026-3557-6","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of Interest. All animal experiments were approved by the Institutional Animal Care and Ethics Committee of Zhengzhou University (ethical number: ZZU-LAC20241227[03]).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethics"}}]}}